TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion
Brief Summary: The purpose of this study is to determine whether bupropion SR increases cessation and/or smoking reduction among pregnant smokers.


Options:
A: Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo
B: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Background:

Aim:

Clinical evaluation of the effectiveness of two different polyethylene glycol doses for the maintenance treatment of functional constipation in children.

Study design:

Randomized, open-label trial.

Randomized, double-blind, placebo controlled trial.


Options:
A: Arm Label: PEG-only; Type: EXPERIMENTAL; Interventions: Device: Polyethylene glycol | Arm Label: PEG-EL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol with electrolytes | Intervention Type: DRUG; Name: Polyethylene glycol with electrolytes; Assigned to Arm(s): PEG-EL | Intervention Type: DEVICE; Name: Polyethylene glycol; Assigned to Arm(s): PEG-only
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PEG 4000 (Forlax®) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactulose active and Lactulose placebo | Intervention Type: DRUG; Name: PEG 4000 (Forlax®); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lactulose active and Lactulose placebo; Assigned to Arm(s): 2
C: Arm Label: Macrogol (Transipeg); Type: EXPERIMENTAL; Interventions: Drug: Macrogol (Transipeg, BAY81-8430) | Arm Label: Macrogol (Forlax); Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrogol (Forlax) | Intervention Type: DRUG; Name: Macrogol (Transipeg, BAY81-8430); Assigned to Arm(s): Macrogol (Transipeg) | Intervention Type: DRUG; Name: Macrogol (Forlax); Assigned to Arm(s): Macrogol (Forlax)
D: Arm Label: Polyethylene glycol small dose; Type: EXPERIMENTAL; Interventions: Drug: Polyethylene glycol 4000 | Arm Label: Polyethylene glycol high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 4000 | Intervention Type: DRUG; Name: Polyethylene glycol 4000; Assigned to Arm(s): Polyethylene glycol high dose, Polyethylene glycol small dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Arm Label: Group A, Sunlight; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight | Arm Label: Group B, sunlight and calcium; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight and calcium | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: Other: control | Intervention Type: OTHER; Name: Sunlight; Assigned to Arm(s): Group A, Sunlight | Intervention Type: OTHER; Name: Sunlight and calcium; Assigned to Arm(s): Group B, sunlight and calcium | Intervention Type: OTHER; Name: control; Assigned to Arm(s): Group C
B: Arm Label: New Flooring; Type: EXPERIMENTAL; Interventions: Other: New flooring | Arm Label: Standard Flooring; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New flooring; Assigned to Arm(s): New Flooring
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
D: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Intervention Type: DRUG; Name: Candesartan cilexetil; Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medication review | Arm Label: Observational arm; Type: OTHER; Interventions: Behavioral: Medication review | Intervention Type: BEHAVIORAL; Name: Medication review; Assigned to Arm(s): Intervention group, Observational arm
C: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
D: Arm Label: Multi-PAP intervention; Type: EXPERIMENTAL; Interventions: Other: Multi-PAP, Other: Usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Multi-PAP; Assigned to Arm(s): Multi-PAP intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Multi-PAP intervention, Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Mirabegron; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Medication Review; Type: EXPERIMENTAL; Interventions: Procedure: Medication Review | Arm Label: Delayed Medication Review; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Medication Review; Assigned to Arm(s): Medication Review
D: Arm Label: Brain Safe App; Type: EXPERIMENTAL; Interventions: Other: Brain Safe App | Arm Label: Attention Control App; Type: SHAM_COMPARATOR; Interventions: Other: Attention Control App | Intervention Type: OTHER; Name: Brain Safe App; Assigned to Arm(s): Brain Safe App | Intervention Type: OTHER; Name: Attention Control App; Assigned to Arm(s): Attention Control App

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial
Brief Summary: Nursing home residents are among the frailest patient groups with a high number of co-morbidities and a high use of medicines. Inappropriate polypharmacy (i.e. often overprescribing) is one of the major problems in the nursing home population increasing the number of adverse drug reactions, falls, hospital admissions, mortality as well as having an impact on health care utilization. Multidisciplinary medication reviews have a great potential to reduce inappropriate medication use. The purpose of this study is to determine the efficacy of a multidisciplinary medication review model focussing on discontinuing inappropriate medication in a cluster randomized controlled trial in 600 nursing home residents. The primary outcome measure is the difference in proportion of residents who successfully discontinued medication between intervention and control group after four months. Secondary outcome measures will be the drug burden index, adverse drug withdrawal events related to the discontinued medication, death, referral to hospitals and quality of life.


Options:
A: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
B: Arm Label: MultiPAP Plus intervention; Type: EXPERIMENTAL; Interventions: Other: MultiPAP Plus, Other: Usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: MultiPAP Plus; Assigned to Arm(s): MultiPAP Plus intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): MultiPAP Plus intervention, Usual care
C: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Other: tele-expertise | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: tele-expertise; Assigned to Arm(s): experimental group
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Brief Summary: In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those people get with recent HIV infection.

Specific objectives:

1. What proportion of people presenting with these symptoms are HIV positive at the point of seeking urgent health care?
2. What proportion of those who test negative or where the result is unclear (one rapid test positive and one negative) at first rapid HIV testing, will test positive two weeks later?
3. What is the best way (SMS, phone call or home visit) to remind people to come for the second test after two weeks?
4. Will young adults who seek urgent health care for fever, body pains, diarrhoea or an STD from pharmacies or health facilities find it acceptable to be invited for an HIV-1 test at the time of health care seeking?

Hypotheses

1. Targeted screening for AHI among patients seeking health care for symptoms compatible with AHI or sexually transmitted disease (STD) will identify AHI cases in more than 1% of those screened.
2. Intense follow-up of patients evaluated for AHI will improve rates of repeat HIV-1 testing 2-4 weeks after initial health-care seeking, relative to standard practice (i.e., recommendation to return for testing on a given date).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text message; Type: ACTIVE_COMPARATOR; Interventions: Other: SMS reminder message | Arm Label: Text message and voice call; Type: ACTIVE_COMPARATOR; Interventions: Other: Voice call + SMS message | Intervention Type: OTHER; Name: SMS reminder message; Assigned to Arm(s): Text message | Intervention Type: OTHER; Name: Voice call + SMS message; Assigned to Arm(s): Text message and voice call
B: Arm Label: The Cedar Project mHealth Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The Cedar Project mHealth intervention | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Cedar Project mHealth intervention; Assigned to Arm(s): The Cedar Project mHealth Intervention
C: Arm Label: Intense follow up; Type: EXPERIMENTAL; Interventions: Behavioral: intense follow up | Arm Label: standard follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intense follow up; Assigned to Arm(s): Intense follow up
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Contraceptive app instant messages, Other: Mobile phone app | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Mobile phone app | Intervention Type: BEHAVIORAL; Name: Contraceptive app instant messages; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Mobile phone app; Assigned to Arm(s): Control, Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Brief Summary: In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those people get with recent HIV infection.

Specific objectives:

1. What proportion of people presenting with these symptoms are HIV positive at the point of seeking urgent health care?
2. What proportion of those who test negative or where the result is unclear (one rapid test positive and one negative) at first rapid HIV testing, will test positive two weeks later?
3. What is the best way (SMS, phone call or home visit) to remind people to come for the second test after two weeks?
4. Will young adults who seek urgent health care for fever, body pains, diarrhoea or an STD from pharmacies or health facilities find it acceptable to be invited for an HIV-1 test at the time of health care seeking?

Hypotheses

1. Targeted screening for AHI among patients seeking health care for symptoms compatible with AHI or sexually transmitted disease (STD) will identify AHI cases in more than 1% of those screened.
2. Intense follow-up of patients evaluated for AHI will improve rates of repeat HIV-1 testing 2-4 weeks after initial health-care seeking, relative to standard practice (i.e., recommendation to return for testing on a given date).


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Quit4Baby, Behavioral: Text4Baby | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Text4Baby | Intervention Type: BEHAVIORAL; Name: Quit4Baby; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Text4Baby; Assigned to Arm(s): Control, Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
C: N/A
D: Arm Label: Intense follow up; Type: EXPERIMENTAL; Interventions: Behavioral: intense follow up | Arm Label: standard follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intense follow up; Assigned to Arm(s): Intense follow up

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?
Brief Summary: The investigators want to test if it is indicated to associate dexamethasone and ondansetron in obese patients having bariatric surgery under total intra-venous closed-loop anesthesia.


Options:
A: Arm Label: Aprepitant group; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant group | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo group
B: Arm Label: Dexamethasone and Ondansetron; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone and Ondansetron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone and Ondansetron; Assigned to Arm(s): Dexamethasone and Ondansetron | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ondansetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: Granisetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granisetron | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Granisetron
D: Arm Label: Arm 1 : Droperidol 1,25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Arm Label: Arm 2 : Droperidol 0,625 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Arm Label: Arm 3 : Odansetron 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Intervention Type: DRUG; Name: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration; Assigned to Arm(s): Arm 1 : Droperidol 1,25 mg, Arm 2 : Droperidol 0,625 mg, Arm 3 : Odansetron 4 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Brief Summary: This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patients with other MSI positive cancers.


Options:
A: Arm Label: A-immunotherapy; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa-2a, Drug: Interleukin-2 | Arm Label: B-follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interferon Alfa-2a; Assigned to Arm(s): A-immunotherapy | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): A-immunotherapy
B: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
C: Arm Label: Cohort A: MSI Positive Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort B: MSI Negative Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort C: MSI Positive Non-Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Intervention Type: DRUG; Name: MK-3475; Assigned to Arm(s): Cohort A: MSI Positive Colorectal Cancer, Cohort B: MSI Negative Colorectal Cancer, Cohort C: MSI Positive Non-Colorectal Cancer
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2

Answer: C